The Dry Age-related Macular Degeneration market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dry Age-related Macular Degeneration pipeline products will significantly revolutionize the Dry Age-related Macular Degeneration market dynamics.
DelveInsight’s “Dry Age-related Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034″ report offersan in-depth understanding of the Dry Age-related Macular Degeneration, historical and forecasted epidemiology as well as the Dry Age-related Macular Degeneration market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Dry Age-related Macular Degeneration market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Dry Age-related Macular Degeneration market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dry Age-related Macular Degeneration Market Insights
Some of the key facts of the Dry Age-related Macular Degeneration Market Report:
-
The Dry Age-related Macular Degeneration market size was valued at USD 1.3 billion in the year 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
-
In January 2024, Tilak Healthcare, a digital health company based in France, revealed promising outcomes from a clinical study evaluating a mobile application designed to enable individuals with chronic macular degeneration to track their vision. Known as TIL002, this multicenter trial conducted across three French hospitals showcased that the OdySight app, which holds a CE mark, exhibited strong agreement with conventional methods used to assess vision deterioration.
-
In December 2023, Laboratoires Théa acquired two promising antisense oligonucleotide (AON) therapies for inherited retinal diseases from ProQR Therapeutics.
-
In August 2023, MeiraGTx reported the completion of enrollment for the Phase III LUMEOS clinical trial for botaretigene sparoparvovec, intended for the treatment of X-linked retinitis pigmentosa (XLRP).
-
In 2023, there were approximately 274,000 prevalent cases of retinitis pigmentosa in the 7MM, and it is anticipated that this number will rise during the projected period.
-
In the 7MM, nonsyndromic retinitis pigmentosa is more common than syndromic retinitis pigmentosa, with approximately 187,000 cases reported in 2023.
-
In 2023, autosomal dominant retinitis pigmentosa stood out as the most prevalent form among common types of retinitis pigmentosa in the United States, with approximately 22,000 reported cases. This includes autosomal recessive retinitis pigmentosa, X-linked retinitis pigmentosa, sporadic/simplex cases, and Leber congenital amaurosis (LCA).
-
Information from multiple sources including the American Macular Degeneration Foundation (2022), Prevent Blindness (2022), Fort Lauderdale Eye Institute (2022), among others, was analyzed. The review indicated that approximately 85–90% of macular degeneration cases are classified as the "dry" (atrophic) type.
-
In 2022, there were an estimated 11 million diagnosed cases of dry age-related macular degeneration (AMD) in the United States.
-
Additional findings indicate that individuals diagnosed with early or intermediate age-related macular degeneration (AMD) make up around 85–90% of all AMD cases, and approximately 10–15% of these patients eventually progress to the wet form of the disease. Geographic atrophy (GA) accounts for half of the exudative form of AMD.
-
In the United States in 2022, there were approximately 10 million diagnosed cases of dry age-related macular degeneration (AMD) classified as early or intermediate stages, and 1 million cases categorized as advanced dry AMD, specifically geographic atrophy associated with dry AMD.
-
Key Dry Age-related Macular Degeneration Companies: Apellis Pharmaceuticals, Iveric bio., Belite Bio, Novartis, CellCure Neurosciences, Allegro Ophthalmics, Stealth BioTherapeutics Inc., Luxa Biotechnology, LLC, Smilebiotek Zhuhai Limited, Gyroscope Therapeutics Limited, Hoffmann-La Roche, Allegro Ophthalmics, LLC, Astellas Institute for Regenerative, Sucampo Pharma Americas, LLC, Novartis, University of California, San Francisco, StemCells, Inc., Acuity Medical International, Sirion Therapeutics, Inc., IVERIC bio, Inc., Kubota Vision Inc., Eyestem Research Pvt. Ltd., Gyroscope Therapeutics, and others
-
Key Dry Age-related Macular Degeneration Therapies: Pegcetacoplan, Zimura, Tinlarebant, PPY988/GT005, OpRegen, Luminate, Elamipretide, RPESC-RPE-4W, QA102/Placebo, GT005, OpRegen, Risuteganib, MA09-hRPE, unoprostone isopropyl, Iptacopan (LNP023), Metformin, HuCNS-SC cells, Tesmac, Fenretinide, Zimura, ACU-4429, Eyecyte-RPE™, GT005, and others
-
The Dry Age-related Macular Degeneration market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dry Age-related Macular Degeneration pipeline products will significantly revolutionize the Dry Age-related Macular Degeneration market dynamics.
Dry Age-related Macular Degeneration Overview
Dry age-related macular degeneration (AMD) is a common eye condition that affects the macula, a small area near the center of the retina responsible for sharp, central vision. In dry AMD, the cells of the macula gradually break down, leading to a gradual loss of central vision over time.
Get a Free sample for the Dry Age-related Macular Degeneration Market Report:
https://www.delveinsight.com/report-store/dry-age-macular-degeneration-market
Dry Age-related Macular Degeneration Market
The dynamics of the Dry Age-related Macular Degeneration market are anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period 2020-2034.
Dry Age-related Macular Degeneration Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Dry Age-related Macular Degeneration Epidemiology Segmentation:
The Dry Age-related Macular Degeneration market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
-
Total Prevalence of Dry Age-related Macular Degeneration
-
Prevalent Cases of Dry Age-related Macular Degeneration by severity
-
Gender-specific Prevalence of Dry Age-related Macular Degeneration
-
Diagnosed Cases of Episodic and Chronic Dry Age-related Macular Degeneration
Download the report to understand which factors are driving Dry Age-related Macular Degeneration epidemiology trends @ Dry Age-related Macular Degeneration Epidemiological Insights
Dry Age-related Macular Degeneration Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dry Age-related Macular Degeneration market or expected to get launched during the study period. The analysis covers Dry Age-related Macular Degeneration market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Dry Age-related Macular Degeneration Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Dry Age-related Macular Degeneration Therapies and Key Companies
-
Pegcetacoplan: Apellis Pharmaceuticals
-
Zimura: Iveric bio.
-
Tinlarebant: Belite Bio
-
PPY988/GT005: Novartis
-
OpRegen: CellCure Neurosciences
-
Luminate: Allegro Ophthalmics
-
Elamipretide: Stealth BioTherapeutics Inc.
-
RPESC-RPE-4W: Luxa Biotechnology, LLC
-
QA102/Placebo: Smilebiotek Zhuhai Limited
-
GT005: Gyroscope Therapeutics Limited
-
OpRegen: Hoffmann-La Roche
-
Risuteganib: Allegro Ophthalmics, LLC
-
MA09-hRPE: Astellas Institute for Regenerative
-
unoprostone isopropyl: Sucampo Pharma Americas, LLC
-
Iptacopan (LNP023): Novartis
-
Metformin: University of California, San Francisco
-
HuCNS-SC cells: StemCells, Inc.
-
Tesmac: Acuity Medical International
-
Fenretinide: Sirion Therapeutics, Inc.
-
Zimura: IVERIC bio, Inc.
-
ACU-4429: Kubota Vision Inc.
-
Eyecyte-RPE™: Eyestem Research Pvt. Ltd.
-
GT005: Gyroscope Therapeutics
To know more about Dry Age-related Macular Degeneration treatment, visit @ Dry Age-related Macular Degeneration Medications
Dry Age-related Macular Degeneration Market Strengths
-
• AAVs have emerged as the predominant vectors for delivering genes of interest to target tissues with improved specificity, efficiency, and safety in the case of retinitis pigmentosa.
-
Gene therapy is advancing by leaps and bounds as it is more effective, less invasive, and relatively safer in the short term than retinal transplantation.
Dry Age-related Macular Degeneration Market Opportunities
-
Alongside advances in cell and gene technologies, research advances in the fields of optogenetics and electronic retinal prostheses also represent encouraging progress for the treatment of retinitis pigmentosa and other inherited retinal dystrophies.
-
Cell therapies such as jCell by jCyte, once approved, will likely have a broad application as they are mutation-independent. Treatment can be initiated earlier as cell therapies do not require genetic testing.
Scope of the Dry Age-related Macular Degeneration Market Report
-
Study Period: 2020–2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Dry Age-related Macular Degeneration Companies: Apellis Pharmaceuticals, Iveric bio., Belite Bio, Novartis, CellCure Neurosciences, Allegro Ophthalmics, Stealth BioTherapeutics Inc., Luxa Biotechnology, LLC, Smilebiotek Zhuhai Limited, Gyroscope Therapeutics Limited, Hoffmann-La Roche, Allegro Ophthalmics, LLC, Astellas Institute for Regenerative, Sucampo Pharma Americas, LLC, Novartis, University of California, San Francisco, StemCells, Inc., Acuity Medical International, Sirion Therapeutics, Inc., IVERIC bio, Inc., Kubota Vision Inc., Eyestem Research Pvt. Ltd., Gyroscope Therapeutics, and others
-
Key Dry Age-related Macular Degeneration Therapies: Pegcetacoplan, Zimura, Tinlarebant, PPY988/GT005, OpRegen, Luminate, Elamipretide, RPESC-RPE-4W, QA102/Placebo, GT005, OpRegen, Risuteganib, MA09-hRPE, unoprostone isopropyl, Iptacopan (LNP023), Metformin, HuCNS-SC cells, Tesmac, Fenretinide, Zimura, ACU-4429, Eyecyte-RPE™, GT005, and others
-
Dry Age-related Macular Degeneration Therapeutic Assessment: Dry Age-related Macular Degeneration current marketed and Dry Age-related Macular Degeneration emerging therapies
-
Dry Age-related Macular Degeneration Market Dynamics: Dry Age-related Macular Degeneration market drivers and Dry Age-related Macular Degeneration market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Dry Age-related Macular Degeneration Unmet Needs, KOL’s views, Analyst’s views, Dry Age-related Macular Degeneration Market Access and Reimbursement
Discover more about therapies set to grab major Dry Age-related Macular Degeneration market share @ Dry Age-related Macular Degeneration market forecast
Table of Contents
1. Dry Age-related Macular Degeneration Market Report Introduction
2. Executive Summary for Dry Age-related Macular Degeneration
3. SWOT analysis of Dry Age-related Macular Degeneration
4. Dry Age-related Macular Degeneration Patient Share (%) Overview at a Glance
5. Dry Age-related Macular Degeneration Market Overview at a Glance
6. Dry Age-related Macular Degeneration Disease Background and Overview
7. Dry Age-related Macular Degeneration Epidemiology and Patient Population
8. Country-Specific Patient Population of Dry Age-related Macular Degeneration
9. Dry Age-related Macular Degeneration Current Treatment and Medical Practices
10. Dry Age-related Macular Degeneration Unmet Needs
11. Dry Age-related Macular Degeneration Emerging Therapies
12. Dry Age-related Macular Degeneration Market Outlook
13. Country-Wise Dry Age-related Macular Degeneration Market Analysis (2020–2034)
14. Dry Age-related Macular Degeneration Market Access and Reimbursement of Therapies
15. Dry Age-related Macular Degeneration Market Drivers
16. Dry Age-related Macular Degeneration Market Barriers
17. Dry Age-related Macular Degeneration Appendix
18. Dry Age-related Macular Degeneration Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
